Lexicon Director Adds $147,000 in Stock as Company Advances Pilavapadin to Phase 3
Raymond Debbane, a member of Lexicon Pharmaceuticals' board, acquired 100,000 common shares on February 23, 2026, investing $147,000. The transaction occurred as the company concluded a major equity raise and received FDA clearance to move its investigational therapy pilavapadin into Phase 3 testing for diabetic peripheral neuropathic pain.